Search Results

Showing 10 from 30 results

Teva to Present Data Highlighting SD 809 at 20th International Congress of Parkinson s Disease and Movement Disorders

Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia

Teva to Present Data from 18 Abstracts in Tardive Dyskinesia and Huntington Disease at the 21st International Congress of Parkinson s Disease and Movement Disorders

Facts Figures

Teva Advances Pipeline of Movement Disorder Assets with Announcement of Positive Top Line Data from the First Pivotal Study of Investigational Treatment for Patients with Tardive Dyskinesia

A Loved One s Perspective on Living with Tardive Dyskinesia

The emotional impact that a movement disorder like tardive dyskinesia TD can have on mental health can be very heavy

Teva to Present Data Highlighting Company s Pipeline in Neurological Disorders at 68th AAN Annual Meeting

What Teva Is Doing to Help Save the Lives of Thousands of Children with Cancer and Blood Disorders in Africa

Helping Address the Impact of Tardive Dyskinesia

Dr Richard Jackson Assistant Clinical Adjunct Professor University of Michigan School of Medicine Department of Psychiatry discusses the challenges both patients and doctors face when it comes to discussing the impact that tardive dyskinesia can have on patients lives which led to the creation of the IMPACT TD scale

7 Ways Teva is Collaborating to Innovate

Focusing on growth potential Teva will continue to develop new collaborations with selected partners to expand reach and promote innovation Already known around the world for its strong generics offering as a company with a category defying portfolio Teva is harnessing its generics expertise and stepping up production of innovative medicines and biosimilars Read on to discover 7 new and exciting collaborations that are currently underway to better serve patients and health communities Because at Teva we are all in for better health